Deciphering the Antitumor Potential of BI 836845: A Human IGF-Neutralizing Antibody
In a pharmacodynamic study involving growing rats, BI 836845 showed inhibition of IGF bioactivity at various dosages, leading to a significant reduction in body weight gain. This suggests that the antibody affects the IGFs' role in growth and development. Additionally, BI 836845 demonstrated a strong inhibitory effect on the proliferation of various cancer cell lines, with mesenchymal-derived cells showing particular sensitivity.
In a study on Ewing's sarcoma using mice, BI 836845 partially inhibited tumor growth when administered twice weekly. The combination of BI 836845 with rapamycin enhanced the therapeutic effect at tolerable doses. Overall, BI 836845 is a potential candidate for clinical trials due to its ability to neutralize IGF ligands effectively.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.
Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.
By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.
Click on the image below to go directly to the Translational Medicine search interface.
